p53 Expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1388-1393

  Daidone, M G ^a   Benini, E ^a   Valentinis, B ^a   Tomasic, G ^a   Bolis, G ^b   Villa, A ^b   Silvestrini, R ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Interlesional heterogeneity; Ovarian surface epithelial stromal tumour; P53; Ploidy; Proliferative activity; Synchronous lesions

Indexed keywords

PROTEIN P53;

ARTICLE; CELL PROLIFERATION; DNA CONTENT; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0030055060     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00101-3     Document Type: Article

References (39)

1. Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol 1986, 4, 244-257.
2. Feichter GE, Kaufmann M, Muller A, Haag D, Eckhardt R, Goerttler K. DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases. Breast Cancer Res Treat 1989, 13, 17-22.
3. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982, 217, 998-1003.
4. Daidone MG, Silvestrini R, Valentinis B, et al. Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H] thymidine labelling index. Cell Tissue Kinet 1990, 23, 401-408.
5. Silvestrini R, Daidone MG, Bolis G, et al. Cell kinetics: a prognostic marker in epithelial ovarian cancer. Gynecol Oncol 1989, 35, 15-19.
6. Davidoff AM, Kerns BM, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991, 51, 2605-2610.
7. Nicolson GL. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993, 204, 171-180.
8. Brison O. Gene amplification and tumor progression. Biochim Biophys Acta 1993, 1155, 25-41.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
10. Bauknecht T, Birmelin G, Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. J Steroid Biochem Molec Biol 1990, 37, 855-862.
11. Liehr T, Atanasov N, Tulusan HT, Gebhart E. Amplification of proto-oncogenes in human ovarian carcinomas. Int J Oncol 1993, 2, 155-160.
12. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991, 51, 5171-5176.
13. Foulkes WD, Black DM, Stamp GWL, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 1993, 54, 220-225.
14. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993, 53, 2128-2132.
15. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991, 6, 1685-1690.
16. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992, 83, 978-984.
17. Eccles DM, Brett L, Lessells A, et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992, 65, 40-44.
18. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutations of p53 in epithelial ovarian cancer. Cancer Res 1991, 51, 2979-2984.
19. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993, 24, 1175-1179.
20. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994, 12, 64-69.
21. Ayhan A, Yasui W, Yokozaki H, Ito H, Tahara E. Genetic abnormalities and expression of p53 in human colon carcinomas. Int J Oncol 1992, 1, 431-437.
22. Costa A, Marasca R, Valentinis B, et al. p53 gene point mutations in relation to P53 nuclear protein accumulation in colorectal cancers. J Pathol 1995, 176, 45-53.
23. Kovach JS, McGovern RM, Cassady JD, et al. Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst 1991, 83, 1004-1009.
24. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85, 200-206.
25. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994, 69, 409-416.
26. Chang F, Syrjänen S, Tervahauta A, Syrjänen K. Tumorigenesis associated with the p53 tumour suppressor gene. Br J Cancer 1993, 68, 653-661.
27. Silvestrini R, Daidone MG, Valentinis B, et al. Potentials of cell kinetics in the management of patients with ovarian cancers. Eur J Cancer 1992, 28, 386-390.
28. Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988, 6, 282-290.
29. Conte PF, Alama A, Rubagotti A, et al. Cell kinetics in ovarian cancer: relation to clinico-pathologic features, responsiveness to chemotherapy and survival. Cancer 1989, 64, 1188-1192.
30. Silvestrini R, Benini E, Daidone MG, et al. P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993, 85, 965-970.
31. Silvestrini R, Daidone MG, Del Bino G, et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 1993, 4, 213-219.
32. Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 1994, 9, 97-102.
33. Bartkova J, Bartek J, Vojtesek B, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993, 29A, 881-886.
34. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994, 9, 603-609.
35. Friedlander ML, Taylor IW, Russell P, Tattersall MHN. Cellular DNA content a stable feature in epithelial ovarian cancer. Br J Cancer 1984, 49, 173-179.
36. Del Bino G, Silvestrini R, Zucconi MR, et al. DNA ploidy of human breast cancer. Anal Cell Pathol 1989, 1, 215-223.
37. Daidone MG, Silvestrini R, Luisi A et al. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 1995, 61, 301-305.
38. Silvestrini R, Valentinis B, Daidone MG, Di Fronzo G, Coradini D, Salvadori B. Biological characterisation of primary and metachronous lesions in breast cancer patients. Eur J Cancer 1992, 28A, 2006-2010.
39. White E. p53, guardian of Rb. Nature 1994, 371, 21-22.